[Form 4] Strata Critical Medical, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Strata Critical Medical (SRTA) reported an insider transaction: Co‑CEO and General Counsel Melissa M. Tomkiel exercised stock options (code M) for 55,555 Class A shares at $0.18 on 10/10/2025.

Following the transaction, she beneficially owned 1,214,816 shares directly, and held 360,294 stock options outstanding. The option grant was originally exercisable from 05/07/2021 and expires 07/28/2030.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Tomkiel Melissa M.

(Last) (First) (Middle)

C/O STRATA CRITICAL MEDICAL, INC.

31 HUDSON YARDS, 14TH FLOOR

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Strata Critical Medical, Inc. [ SRTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-CEO and General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
10/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A common stock, $0.0001 par value per share	10/10/2025		M		55,555	A	$0.18	1,214,816	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.18	10/10/2025		M			55,555	05/07/2021	07/28/2030	Class A common stock, $0.0001 par value per share	55,555	$0	360,294	D

Explanation of Responses:

Remarks:

	/s/ Melissa M. Tomkiel	10/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did SRTA disclose in this Form 4?

Co‑CEO and General Counsel Melissa M. Tomkiel exercised options (code M) for 55,555 Class A shares at $0.18 on 10/10/2025.

How many SRTA shares does the insider own after the transaction?

Following the transaction, she beneficially owned 1,214,816 shares directly.

What options remain for the insider at SRTA?

She held 360,294 stock options outstanding after the reported transaction.

What are the key terms of the exercised SRTA option?

The option had an exercise price of $0.18, was exercisable from 05/07/2021, and expires on 07/28/2030.

Who is the reporting person in SRTA’s Form 4?

The reporting person is Melissa M. Tomkiel, SRTA’s Co‑CEO and General Counsel, who also serves as a Director.

What was the transaction code in SRTA’s Form 4 and what does it indicate?

The transaction code is M, indicating an option exercise resulting in acquisition of underlying shares.